Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045004080> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2045004080 endingPage "e474" @default.
- W2045004080 startingPage "e473" @default.
- W2045004080 abstract "Introduction: New onset diabetes mellitus (NOD) represents an adverse complication during long-term treatment of cardiovascular (CV) disease, mostly hypertension, being related to a significant increase in CV morbidity and mortality. Retrospective analyses suggested that the use of drugs that counteract Renin-Angiotensin System (RAS) may significantly reduce NOD incidence, while use of beta-blockers and thiazide diuretics have been associated to an increased risk of NOD. The recent results of ONTARGET/TRANSCEND and PROFESS trials, however, have questioned this issue. Objective: To evaluate the efficacy of ACE Inhibitors and Angiotensin II Receptor Blockers (ARBs) in term of incidence of NOD in international, randomised, placebo-controlled clinical trials. Design and Method: We performed a comprehensive meta-analysis of all available clinic trials performed with ACE Inhibitors (SOLVD, HOPE, PEACE e DREAM) or ARBs (CHARM, SCOPE, TRANSCEND, PROFESS), published within December 31 2009 (8 trials, n = 63.715 patients, mean age 65.7 ± 6.3 years), which reported NOD incidence, either as predefined CV endpoint or as drug-related adverse event, as compared to placebo in different clinical conditions. Results: During a mean follow-up of 3.7 ± 0.9 years, we recorded 886/10540 cases in the ACE Inhibitor group, 740/17552 cases in the ARB group and 1875/22880 cases in the placebo group. Antihypertensive therapy based on ACE Inhibitors reduced NOD incidence (OR 0,7288; 95% IC 0,5438–0,9768), although this reduction did not achieve statistically significance; at the same time, antihypertensive strategy based on ARBs significantly reduced NOD incidence as compared to placebo (OR 0,8395; 95% IC 0,7573–0,9306) in clinical trials performed in high risk patients, with or without heart failure. Overall, RAS blocking agents significantly reduced NOD incidence as compared to placebo (OR 0,8498; 95% IC 0,7917–0,9122). Conclusions: The clinical use of RAS blocking agents significantly reduced NOD incidence in placebo-controlled clinical trials in high risk patients, with or without heart failure." @default.
- W2045004080 created "2016-06-24" @default.
- W2045004080 creator A5014433377 @default.
- W2045004080 creator A5028634699 @default.
- W2045004080 creator A5031467506 @default.
- W2045004080 creator A5041331125 @default.
- W2045004080 creator A5050799541 @default.
- W2045004080 creator A5054282642 @default.
- W2045004080 creator A5072215221 @default.
- W2045004080 creator A5084756058 @default.
- W2045004080 date "2010-06-01" @default.
- W2045004080 modified "2023-09-25" @default.
- W2045004080 title "NEW ONSET DIABETES MELLITUS IN RANDOMISED CLINICAL TRIALS PERFORMED WITH ACE INHIBITORS OR ANGIOTENSIN II RECEPTOR BLOCKERS: AN UPDATED META-ANALYSIS VERSUS PLACEBO: PP.27.88" @default.
- W2045004080 doi "https://doi.org/10.1097/01.hjh.0000379626.41281.14" @default.
- W2045004080 hasPublicationYear "2010" @default.
- W2045004080 type Work @default.
- W2045004080 sameAs 2045004080 @default.
- W2045004080 citedByCount "0" @default.
- W2045004080 crossrefType "journal-article" @default.
- W2045004080 hasAuthorship W2045004080A5014433377 @default.
- W2045004080 hasAuthorship W2045004080A5028634699 @default.
- W2045004080 hasAuthorship W2045004080A5031467506 @default.
- W2045004080 hasAuthorship W2045004080A5041331125 @default.
- W2045004080 hasAuthorship W2045004080A5050799541 @default.
- W2045004080 hasAuthorship W2045004080A5054282642 @default.
- W2045004080 hasAuthorship W2045004080A5072215221 @default.
- W2045004080 hasAuthorship W2045004080A5084756058 @default.
- W2045004080 hasBestOaLocation W20450040801 @default.
- W2045004080 hasConcept C120665830 @default.
- W2045004080 hasConcept C121332964 @default.
- W2045004080 hasConcept C126322002 @default.
- W2045004080 hasConcept C134018914 @default.
- W2045004080 hasConcept C142724271 @default.
- W2045004080 hasConcept C197934379 @default.
- W2045004080 hasConcept C204787440 @default.
- W2045004080 hasConcept C27016395 @default.
- W2045004080 hasConcept C27081682 @default.
- W2045004080 hasConcept C2779611605 @default.
- W2045004080 hasConcept C535046627 @default.
- W2045004080 hasConcept C555293320 @default.
- W2045004080 hasConcept C61511704 @default.
- W2045004080 hasConcept C71924100 @default.
- W2045004080 hasConcept C84393581 @default.
- W2045004080 hasConcept C98274493 @default.
- W2045004080 hasConceptScore W2045004080C120665830 @default.
- W2045004080 hasConceptScore W2045004080C121332964 @default.
- W2045004080 hasConceptScore W2045004080C126322002 @default.
- W2045004080 hasConceptScore W2045004080C134018914 @default.
- W2045004080 hasConceptScore W2045004080C142724271 @default.
- W2045004080 hasConceptScore W2045004080C197934379 @default.
- W2045004080 hasConceptScore W2045004080C204787440 @default.
- W2045004080 hasConceptScore W2045004080C27016395 @default.
- W2045004080 hasConceptScore W2045004080C27081682 @default.
- W2045004080 hasConceptScore W2045004080C2779611605 @default.
- W2045004080 hasConceptScore W2045004080C535046627 @default.
- W2045004080 hasConceptScore W2045004080C555293320 @default.
- W2045004080 hasConceptScore W2045004080C61511704 @default.
- W2045004080 hasConceptScore W2045004080C71924100 @default.
- W2045004080 hasConceptScore W2045004080C84393581 @default.
- W2045004080 hasConceptScore W2045004080C98274493 @default.
- W2045004080 hasLocation W20450040801 @default.
- W2045004080 hasLocation W20450040802 @default.
- W2045004080 hasOpenAccess W2045004080 @default.
- W2045004080 hasPrimaryLocation W20450040801 @default.
- W2045004080 hasRelatedWork W1964352248 @default.
- W2045004080 hasRelatedWork W2007458456 @default.
- W2045004080 hasRelatedWork W2085830368 @default.
- W2045004080 hasRelatedWork W2095893657 @default.
- W2045004080 hasRelatedWork W2182673189 @default.
- W2045004080 hasRelatedWork W2741632583 @default.
- W2045004080 hasRelatedWork W2782950959 @default.
- W2045004080 hasRelatedWork W4238863659 @default.
- W2045004080 hasRelatedWork W4283171304 @default.
- W2045004080 hasRelatedWork W4295873639 @default.
- W2045004080 hasVolume "28" @default.
- W2045004080 isParatext "false" @default.
- W2045004080 isRetracted "false" @default.
- W2045004080 magId "2045004080" @default.
- W2045004080 workType "article" @default.